AMSBIO Launch Novel Microfluidic Oncology Screen

AMSBIO, a transatlantic life sciences company, and the University of Strathclyde (Glasgow, UK) have pioneered a multidisciplinary approach combining expertise in microfluidics and 3D culture to develop a novel microfluidic platform for cancer research. The new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular...

Original Article: AMSBIO Launch Novel Microfluidic Oncology Screen

More From BioPortfolio on "AMSBIO Launch Novel Microfluidic Oncology Screen"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications